Literature DB >> 33030432

Efficacy of Benralizumab and Clinical Course of IgG4 in Eosinophilic Granulomatosis With Polyangiitis.

Y Miyata1, H Inoue1, T Homma1, A Tanaka1, H Sagara1.   

Abstract

Entities:  

Keywords:  Anti-IL-5 receptor antibody; Benralizumab; Eosinophilic granulomatosis with polyangiitis (EGPA); IgG4; MPO-ANCA

Mesh：

Substances：

Year:  2020        PMID： 33030432     DOI： 10.18176/jiaci.0648

Source DB:  PubMed          Journal:  J Investig Allergol Clin Immunol        ISSN： 1018-9068            Impact factor:   4.333


× No keyword cloud information.
  4 in total

Review 1.  Perspectives on the Efficacy of Benralizumab for Treatment of Eosinophilic Granulomatosis With Polyangiitis.

Authors:  Yasuhiko Koga; Haruka Aoki-Saito; Yosuke Kamide; Makiko Sato; Hiroaki Tsurumaki; Masakiyo Yatomi; Tamotsu Ishizuka; Takeshi Hisada
Journal:  Front Pharmacol       Date:  2022-03-10       Impact factor: 5.810

2.  Case Report: Severe Eosinophilic Asthma Associated With ANCA-Negative EGPA in a Young Adult Successfully Treated With Benralizumab.

Authors:  Luisa Ricciardi; Daniel Griscti Soler; Alessandra Bennici; Silvia Brunetto; Giovanni Pioggia; Sebastiano Gangemi
Journal:  Front Pharmacol       Date:  2022-04-07       Impact factor: 5.988

Review 3.  Allergic Aspects of IgG4-Related Disease: Implications for Pathogenesis and Therapy.

Authors:  Despina Michailidou; Daniella Muallem Schwartz; Tomas Mustelin; Grant C Hughes
Journal:  Front Immunol       Date:  2021-07-07       Impact factor: 7.561

4.  Successful treatment with benralizumab in a patient with eosinophilic granulomatosis with polyangiitis refractory to mepolizumab.

Authors:  Francesco Menzella; Carla Galeone; Giulia Ghidoni; Patrizia Ruggiero; Silvia Capobelli; Anna Simonazzi; Chiara Catellani; Chiara Scelfo; Francesco Livrieri; Nicola Facciolongo
Journal:  Multidiscip Respir Med       Date:  2021-06-24
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.